By Rosanne Fohn
|Guest faculty for the conference included (left to right) Craig Reynolds, M.D., development chair in lung cancer at U.S. Oncology Research; Ken Anderson, M.D., Kraft Family Professor of Medicine at Harvard Medical School; and Dan Von Hoff, M.D., FACP, physician-in-chief and distinguished professor in the Translational Research Division at Translational Genomics Research Institute in Phoenix, Ariz. |
Printer Friendly Format
One hundred thirty physicians and oncology researchers recently attended the “Practical Applications of New Agents in Oncology” conference held Feb. 22-23.
The conference was hosted by the Institute for Drug Development
, part of the Cancer Therapy & Research Center
at the UT Health Science Center San Antonio. It was held at the Greehey Children’s Cancer Research Institute.
The meeting focused on new anticancer drugs and related therapeutics that have been approved in the past few years, as well as those likely to be approved in the near future.
“We were very pleased with the turnout and interest in the conference by physicians from the surrounding area as well as from outside of the State,” said Steve Weitman, M.D., Ph.D.
, director of the Institute for Drug Development and the AT&T Distinguished Chair of Drug Development.
|Tyler Curiel, M.D., M.P.H., professor of medicine in the Division of Hematology/Oncology, was one of several UT Health Science Center San Antonio faculty members who gave presentations at the conference. |
“The conference covered some of the most important new drugs and therapies available for brain tumors, multiple myeloma, pancreatic cancer, ovarian and breast cancer, lung cancer, sarcoma, and leukemia and lymphoma,” Dr. Weitman said. “We also discussed how these new drugs could interact with other medications that cancer patients may be taking as well as the importance of physical activity in the treatment of cancer.”Slides from the presentations
will be available on the CTRC website through March 31.